Abstract Library

#4049 A prospective, open-label study evaluating the efficacy and safety of Surufatinib (S) in combination with CAPTEM as conversion therapy in patients with unresectable pancreatic neuroendocrine tumors (pNET)

Introduction: Surgery is the primary treatment and only possible cure for pNET. Unresectable pNET necessitates conversion therapy to obtain opportunity of radical resection. Former trials have shown potential of Surufatinib (S) and CAPTEM as conversion therapy in pNET.

Conference:

Presenting Author: Wang Z

Authors: Wang Z, Cao D, Ke N,

Keywords: pNET, Conversion therapy, Surufatinib, CAPTEM,

#3588 Evaluation of PFS and OS in patients with sporadic, advanced, unresectable, well-differentiated pancreatic neuroendocrine tumors (panNETs) treated initially with Octreotide LAR and methods of further treatment after relapse - Real-world data

Introduction: Evaluation of PFS & OS in patients with sporadic, advanced, unresectable, panNET using first line Octreotide therapy need to be further explored.

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Bednarczuk T, Osowiecka K, Słoniowska A, Roszkowska K,

Keywords: advance, unresectable pancreatic neuroendocrine tumor, initial octreotide LAR therapy, OS, PFS,

#1240 Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors

Introduction: Neuroendocrine tumors are an entity of rare, heterogeneous group of tumors that can arise from different sites within the body. Although number of different treatment types and modalities exist, chemotherapy remains as the first line option in the management of advance pancreatic NETS (pNETS); two targeted therapies, sunitinib and everolimus remains available only for second line and beyond in Canada.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Kavan P

Authors: Rho Y, Gilabert M, McLean J, Kavan P,

Keywords: targeted therapy, sunitinib, everolimus, PNET,